A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
NCT ID: NCT03631186
Last Updated: 2021-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
215 participants
OBSERVATIONAL
2018-09-12
2019-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)
NCT03876015
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)
NCT03929679
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
NCT04067999
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
NCT05533632
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
NCT03457012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Semaglutide
Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
Semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
* Male or female, age greater than or equal to 18 years at the time of signing informed consent
* Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
* Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment
Exclusion Criteria
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Treatment with any investigational drug within 90 days prior to enrolment into the study
* Hypersensitivity to semaglutide or to any of the excipients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Reporting Anchor and Disclosure (1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Ascona, , Switzerland
Novo Nordisk Investigational Site
Baden, , Switzerland
Novo Nordisk Investigational Site
Baden, , Switzerland
Novo Nordisk Investigational Site
Basel, , Switzerland
Novo Nordisk Investigational Site
Bellinzona, , Switzerland
Novo Nordisk Investigational Site
Binningen, , Switzerland
Novo Nordisk Investigational Site
Blonay, , Switzerland
Novo Nordisk Investigational Site
Bülach, , Switzerland
Novo Nordisk Investigational Site
Chiasso, , Switzerland
Novo Nordisk Investigational Site
Estavayer-le-Lac, , Switzerland
Novo Nordisk Investigational Site
Frauenfeld, , Switzerland
Novo Nordisk Investigational Site
Fribourg, , Switzerland
Novo Nordisk Investigational Site
Geneva, , Switzerland
Novo Nordisk Investigational Site
Gland, , Switzerland
Novo Nordisk Investigational Site
Interlaken-Unterseen, , Switzerland
Novo Nordisk Investigational Site
Kleinhüningen, , Switzerland
Novo Nordisk Investigational Site
Lausanne, , Switzerland
Novo Nordisk Investigational Site
Lausanne, , Switzerland
Novo Nordisk Investigational Site
Lugano, , Switzerland
Novo Nordisk Investigational Site
Nürensdorf, , Switzerland
Novo Nordisk Investigational Site
Olten, , Switzerland
Novo Nordisk Investigational Site
Riehen, , Switzerland
Novo Nordisk Investigational Site
Sankt Gallen, , Switzerland
Novo Nordisk Investigational Site
Schaffhausen, , Switzerland
Novo Nordisk Investigational Site
Solothurn, , Switzerland
Novo Nordisk Investigational Site
Viganello, , Switzerland
Novo Nordisk Investigational Site
Zurich, , Switzerland
Novo Nordisk Investigational Site
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rudofsky G, Catarig AM, Favre L, Grau K, Hafliger S, Thomann R, Schultes B. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021 Aug;178:108931. doi: 10.1016/j.diabres.2021.108931. Epub 2021 Jul 1.
Yale JF, Bodholdt U, Catarig AM, Catrina S, Clark A, Ekberg NR, Erhan U, Holmes P, Knudsen ST, Liutkus J, Sathyapalan T, Schultes B, Rudofsky G. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022 Apr;10(2):e002619. doi: 10.1136/bmjdrc-2021-002619.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1207-6039
Identifier Type: OTHER
Identifier Source: secondary_id
NN9535-4443
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.